Outset Medical, Inc. (NASDAQ:OM – Get Rating) CTO Jean-Olivier Racine sold 1,157 shares of Outset Medical stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $14.50, for a total value of $16,776.50. Following the sale, the chief technology officer now directly owns 40,920 shares in the company, valued at approximately $593,340. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ:OM traded up $0.84 during midday trading on Friday, hitting $16.30. 1,072,283 shares of the stock were exchanged, compared to its average volume of 555,560. The company has a current ratio of 7.72, a quick ratio of 6.84 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $779.04 million, a price-to-earnings ratio of -5.38 and a beta of 2.13. Outset Medical, Inc. has a one year low of $13.25 and a one year high of $60.33. The business has a 50-day moving average price of $26.33 and a two-hundred day moving average price of $36.50.
Outset Medical (NASDAQ:OM – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($0.78) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.78). The firm had revenue of $30.55 million for the quarter, compared to analyst estimates of $30.35 million. Outset Medical had a negative net margin of 125.91% and a negative return on equity of 35.58%. Sell-side analysts forecast that Outset Medical, Inc. will post -2.72 EPS for the current fiscal year.
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Institutional investors have recently bought and sold shares of the business. Advisor Group Holdings Inc. grew its position in Outset Medical by 253.6% in the fourth quarter. Advisor Group Holdings Inc. now owns 1,326 shares of the company’s stock worth $61,000 after buying an additional 951 shares during the last quarter. Fieldpoint Private Securities LLC acquired a new position in Outset Medical in the fourth quarter worth approximately $67,000. IFP Advisors Inc acquired a new position in Outset Medical in the fourth quarter worth approximately $82,000. US Bancorp DE grew its position in Outset Medical by 286.7% during the 1st quarter. US Bancorp DE now owns 2,711 shares of the company’s stock worth $123,000 after purchasing an additional 2,010 shares in the last quarter. Finally, Crossmark Global Holdings Inc. purchased a new position in Outset Medical during the 4th quarter worth approximately $216,000.
Several equities research analysts recently commented on OM shares. Bank of America started coverage on Outset Medical in a report on Wednesday, March 2nd. They set a “buy” rating on the stock. Cowen dropped their target price on Outset Medical from $60.00 to $33.00 in a report on Tuesday, June 14th. Stifel Nicolaus dropped their target price on Outset Medical from $55.00 to $30.00 in a report on Tuesday, June 14th. Finally, Cowen dropped their target price on Outset Medical from $60.00 to $33.00 and set an “outperform” rating on the stock in a report on Tuesday, June 14th.
Outset Medical Company Profile (Get Rating)
Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Outset Medical right now?
Before you consider Outset Medical, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Outset Medical wasn’t on the list.
While Outset Medical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
